Abstract

Objective:

To estimate the global prevalence of carpal tunnel syndrome (CTS) in patients with Parkinson’s disease (PD) compared to control groups.

Background:

CTS is a median nerve entrapment in the carpal tunnel. Variability of the prevalence of CTS in PD was described among studies. This systematic review and meta-analysis aimed to investigate the association between CTS and PD by estimating the pooled prevalence of CTS in PD.

Design/Methods:

We conducted a literature search in several databases up to April 2024. Studies that had data about the prevalence of CTS in PD were included. The pooled prevalence was our primary outcome. RD and RR were calculated to investigate the association between CTS and PD compared to the control groups.

Results:

A total of seven articles with 411 participants (343 PD patients and 68 controls) were included.

Using the Fixed-effect model, the pooled prevalence of CTS in PD was estimated to be 20%(95% CI, 0.17; 0.24) while the Random-effect model estimated the pooled prevalence of CTS in PD to be 15%(95% CI, 0.07; 0.28). Despite the heterogeneity(P < 0.001, I2 = 91%), the association between both conditions was reinforced by calculating the RD and the RR.

The RD for CTS in PD was calculated to be 10% (95% CI, 0.04, 0.16),(P=0.29, I2 = 19%). The RR of CTS in PD compared to control groups was estimated to be 3.31 (95% CI, 0.60, 18.42),(P=0.13, I2 = 52%). RD and RR both indicate a statistically significant difference in the association between CTS and PD compared to control groups and indicate that PD patients are more than three times likely to develop CTS compared to non-PD.

Conclusions:

Our study reveals a significant association between CTS and PD. PD patients are more than three times likely to develop CTS compared to non-PD. We would suggest future studies that have larger sample sizes.

Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.

Disclosure: Mr. Attia has nothing to disclose. Dr. Sabry has nothing to disclose. Miss Mohammed has nothing to disclose. Dr. Amin has nothing to disclose. Dr. Ezz has nothing to disclose. Dr. Syed has nothing to disclose. Dr. Bakr has nothing to disclose. Mr. Ibrahim has nothing to disclose. Dr. Shaheen has a non-compensated relationship as a A Research Position Candidate Under Trial Task with Solvemed Company that is relevant to AAN interests or activities. Dr. Saha has nothing to disclose.